Sermorelin vs Ipamorelin vs CJC-1295: GHRH and Ghrelin Receptor Routes Compared
Sermorelin, ipamorelin and CJC-1295 are routinely grouped together as growth hormone secretagogues, which is accurate but hides the more useful distinction. Two of the three act on the growth hormone-releasing hormone receptor. One acts on a different receptor entirely, and that difference is the first thing a study design has to establish.
Two receptor routes, three compounds
Somatotroph cells in the anterior pituitary carry two receptors relevant here. The GHRH receptor responds to growth hormone-releasing hormone, the hypothalamic peptide that drives pulsatile growth hormone release. The growth hormone secretagogue receptor, better known as the ghrelin receptor, responds to ghrelin and to synthetic compounds that mimic it.
Sermorelin and CJC-1295 are GHRH analogues acting at the first receptor. Ipamorelin is a ghrelin receptor agonist acting at the second. That single fact explains most of the differences between them.
Sermorelin
Sermorelin corresponds to the first 29 amino acids of human growth hormone-releasing hormone — the shortest fragment of the parent hormone that retains activity at the GHRH receptor, which is why it became the reference GHRH analogue in the literature.
Being close to the native sequence, it is short-lived in circulation and produces a signal resembling a natural GHRH pulse in shape. That makes it useful where the question concerns pituitary responsiveness rather than sustained receptor occupancy: a short stimulus, a measurable response, a return to baseline.
CJC-1295
CJC-1295 is built on the same 29-amino-acid framework as sermorelin, with substitutions at positions that would otherwise be cleaved rapidly by circulating enzymes. The result is a GHRH-receptor agonist with a longer functional life.
Two forms appear in the literature. The version carrying a drug affinity complex binds serum albumin and persists far longer. The version without it, written as CJC-1295 no DAC, is closer in duration to sermorelin while keeping the stability improvements. The distinction is not cosmetic: the two produce very different exposure profiles, and a paper that does not specify which was used is hard to interpret. Santa Cruz Peptides stocks the no-DAC form, supplied with ipamorelin as CJC-1295 + Ipamorelin (No DAC) 10mg.
Ipamorelin
Ipamorelin is a synthetic pentapeptide and the outlier of the three: no structural relationship to GHRH, and no binding at the GHRH receptor. It is an agonist at the ghrelin receptor, and its standing in the literature rests largely on selectivity — binding studies characterised it as acting on the growth hormone secretagogue receptor with markedly less activity at pathways that earlier secretagogues also engaged. That makes it the usual ghrelin-route comparator in mechanistic work.
Side by side
| Sermorelin | Ipamorelin | CJC-1295 | |
|---|---|---|---|
| Receptor | GHRH receptor | Ghrelin receptor | GHRH receptor |
| Class | GHRH(1-29) analogue | Synthetic pentapeptide | Modified GHRH analogue |
| Relationship to GHRH | Native fragment | None | Substituted fragment |
| Signal character | Short, pulse-like | Ghrelin-route stimulus | Extended, form-dependent |
| Research role | Reference GHRH analogue | Ghrelin-route comparator | Sustained GHRH signalling |
Why the two routes are studied together
A GHRH analogue and a ghrelin receptor agonist reach the same cell through separate front doors, and because the two receptors signal through different intracellular cascades, published preclinical work describes their effects as additive rather than redundant. Studies pairing them are asking whether the two inputs converge, compete or sum — a question neither compound answers alone. The standard design uses each compound singly, the combination, and a control, which is also why combined preparations are a common supply format.
Practical considerations for study design
Three points recur. Specify the CJC-1295 form, since DAC and no-DAC results are not comparable. Allow for different response kinetics between the two routes, because a sampling schedule built around one may miss the other. And keep purity and identity consistent across arms, or the comparison measures supplier variation instead of receptor pharmacology. Santa Cruz Peptides supplies research peptides as lyophilized powder at greater than 98 percent purity, verified by independent HPLC and mass spectrometry testing; our note on third-party certificates of analysis covers what those documents should show.
Frequently Asked Questions
What is the difference between sermorelin and ipamorelin?
They act on different receptors. Sermorelin is a GHRH analogue acting at the growth hormone-releasing hormone receptor. Ipamorelin is a synthetic pentapeptide acting at the ghrelin receptor. The two are not structurally related.
Are sermorelin and CJC-1295 the same thing?
No, but they are closely related. Both are GHRH analogues built on the first 29 amino acids of growth hormone-releasing hormone. CJC-1295 carries substitutions that resist enzymatic breakdown, giving it a longer functional life than sermorelin.
What does no DAC mean on CJC-1295?
DAC stands for drug affinity complex, a modification that binds the peptide to serum albumin and greatly extends its persistence. The no-DAC form lacks that modification and has a much shorter exposure profile, so the two are not interchangeable in a study.
Why are CJC-1295 and ipamorelin supplied together?
They engage the same pituitary cell through two separate receptors, so pairing them is the standard way to examine whether the GHRH and ghrelin routes sum or compete. A single vial removes handling variation between arms.
Where does tesamorelin fit among these?
Tesamorelin is a further GHRH analogue, useful as an additional arm where the question concerns the GHRH receptor specifically rather than growth hormone release in general.
Related Research Peptides
Sermorelin 10mg · Ipamorelin 10mg · CJC-1295 + Ipamorelin (No DAC) 10mg · Tesamorelin 10mg · Tesamorelin 5mg
For Research Use Only
All compounds discussed in this article are supplied strictly for laboratory research purposes. They are not drugs, foods, cosmetics, or dietary supplements, and are not intended to diagnose, treat, cure, or prevent any disease. They are not for human or veterinary consumption. This article summarises published preclinical literature for educational purposes and does not constitute guidance on use of any kind.